The human genome runs to 3bn pairs of letters - the Gs, Ts, Cs and As that comprise the DNA code. The human genome runs to 3bn pairs of letters - the Gs, Ts, Cs and As that comprise the DNA code. Researchers at Google DeepMind have unveiled their latest artificial intelligence tool and claimed it will help scientists identify the genetic drivers of disease and ultimately pave the way for new treatments. AlphaGenome predicts how mutations interfere with the way genes are controlled, changing when they are switched on, in which cells of the body, and whether their biological volume controls are set to high or low. Most common diseases that run in families, including heart disease and autoimmune disorders, as well as mental health problems, have been linked to mutations that affect gene regulation, as have many cancers, but identifying which genetic glitches are to blame is far from straightforward.

AI model from Google's DeepMind reads recipe for life in DNA An AI model developed by Google's DeepMind could transform our understanding of DNA - the complete recipe for building and running the human body - and its impact on disease and medicine discovery, according to researchers. Called AlphaGenome, the model could help scientists discover why subtle differences in our DNA put us at risk of conditions such as high blood pressure, dementia and obesity. It could also dramatically accelerate our understanding of genetic diseases and cancer. The developers of the model acknowledge it's not perfect, but experts have described it as an incredible feat and a major milestone. We see AlphaGenome as a tool for understanding what the functional elements in the genome do, which we hope will accelerate our fundamental understanding of the code of life, says Natasha Latysheva, research engineer at DeepMind.

We investigate the application of Small Language Models (<10 billion parameters) for genomics question answering via agentic framework to address hallucination issues and computational cost challenges. The Nano Bio-Agent (NBA) framework we implemented incorporates task decomposition, tool orchestration, and API access into well-established systems such as NCBI and AlphaGenome. Results show that SLMs combined with such agentic framework can achieve comparable and in many cases superior performance versus existing approaches utilising larger models, with our best model-agent combination achieving 98% accuracy on the GeneTuring benchmark. Notably, small 3-10B parameter models consistently achieve 85-97% accuracy while requiring much lower computational resources than conventional approaches. This demonstrates promising potential for efficiency gains, cost savings, and democratization of ML-powered genomics tools while retaining highly robust and accurate performance.

If you need me after this newsletter publishes, I will be busy poring over photos from Jeff Bezos and Lauren Sanchez's wedding, the gaudiest and most star-studded affair to disrupt technology news this year. I found it a tacky and spectacular affair. Everyone who was anyone was there, except for Charlize Theron, who, unprompted, said on Monday: "I think we might be the only people who did not get an invite to the Bezos wedding. Judge William Alsup compared the Anthropic model's use of books to a "reader aspiring to be a writer." And the next day, Meta: The US district judge Vince Chhabria, in San Francisco, said in his decision on the Meta case that the authors had not presented enough evidence that the technology company's AI would cause "market dilution" by flooding the market with work similar to theirs. Judging by the rulings in favor of Meta and Anthropic, the authors are facing an uphill battle. Three weeks ago, Disney and NBCUniversal sued Midjourney, alleging that the ...

"We haven't designed or validated AlphaGenome for personal genome prediction, a known challenge for AI models," Google said in a statement. Underlying the AI system is the so-called transformer architecture invented at Google that also powers large language models like GPT-4. This one was trained on troves of experimental data produced by public scientific projects. Lareau says the system will not broadly change how his lab works day to day but could permit new types of research. For instance, sometimes doctors encounter patients with ultra-rare cancers, bristling with unfamiliar mutations.